Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation
Category: 2020
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
20200311 Resultats 2019 EN
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
20200303 BT-001 presentations EN
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdfClémentine Spring-Giusti et al.American College of Toxicology – 40th Annual MeetingDownload the poster herePoster Presentation
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation